http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 16:40:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CERENOME%2C+INC.++++++++++++For%3A+Jun+30/26931824.html si-local-file:///var/storage/secattach/20260814/26931824.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CERENOME%2C+INC.++++++++++++For%3A+Jun+30/26931824.html Fri, 14 Aug 2026 16:40:00 -0400 CNSY O.00066617 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CERENOME%2C+INC.++++++++++++For%3A+Jun+30/26931824.html si-local-file:///var/storage/secattach/20260814/26931824.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CERENOME%2C+INC.++++++++++++For%3A+Jun+30/26931824.html Fri, 14 Aug 2026 16:40:00 -0400 CNSY O.00066617 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CERENOME%2C+INC.++++++++++++For%3A+Aug+14/26931235.html si-local-file:///var/storage/secattach/20260814/26931235.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CERENOME%2C+INC.++++++++++++For%3A+Aug+14/26931235.html Fri, 14 Aug 2026 16:28:00 -0400 CNSY O.00066617 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CERENOME%2C+INC.++++++++++++For%3A+Aug+14/26931235.html si-local-file:///var/storage/secattach/20260814/26931235.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CERENOME%2C+INC.++++++++++++For%3A+Aug+14/26931235.html Fri, 14 Aug 2026 16:28:00 -0400 CNSY O.00066617 http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Press+Releases/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html <p align="justify">HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (&quot;Cerenome&quot; or the &quot;Company&quot;), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.</p> <p align="justify">&quot;Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,&quot; said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. &quot;For the remainder of the year, http://www.streetinsider.com/Globe+Newswire/Cerenome+Reports+Second+Quarter+2026+Financial+Results+and+Business+Update/26930541.html Fri, 14 Aug 2026 16:15:00 -0400 A.06822034 A.09717019 A.18499824 A.30142833 A.40958841 A.60001765 CNSY O.00003102 O.00063567 O.00066617 O.03306677 O.20026344 O.20738543 O.36670513 PSTV